Amphastar Pharmaceuticals, Inc. Stock-Based Compensation
Amphastar Pharmaceuticals, Inc. (AMPH) reported Stock-Based Compensation of $16.36 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow › Operating Activities
us-gaap:ShareBasedCompensation · last filed 2026-08-06
- Amphastar Pharmaceuticals, Inc. share-based payment arrangement, noncash expense for the quarter ending 2026-06-30 was $7.09M, a 11.09% increase year-over-year.
- Amphastar Pharmaceuticals, Inc. share-based payment arrangement, noncash expense for the quarter ending 2026-03-31 was $9.27M, a 10.50% increase year-over-year.
- Amphastar Pharmaceuticals, Inc. share-based payment arrangement, noncash expense for the quarter ending 2025-12-31 was $6.21M, a 10.17% increase year-over-year.
- Amphastar Pharmaceuticals, Inc. share-based payment arrangement, noncash expense for the quarter ending 2025-09-30 was $6.30M, a 12.53% increase year-over-year.
- Amphastar Pharmaceuticals, Inc. share-based payment arrangement, noncash expense for fiscal 2025 was $27.28M, a 11.94% increase from fiscal 2024.
- Amphastar Pharmaceuticals, Inc. share-based payment arrangement, noncash expense for fiscal 2024 was $24.37M, a 20.38% increase from fiscal 2023.
- Amphastar Pharmaceuticals, Inc. share-based payment arrangement, noncash expense for fiscal 2023 was $20.24M, a 13.34% increase from fiscal 2022.
- Amphastar Pharmaceuticals, Inc. share-based payment arrangement, noncash expense for fiscal 2022 was $17.86M, a 4.43% decline from fiscal 2021.
| Period end | Share-based Payment Arrangement, Noncash Expense 3 month | Share-based Payment Arrangement, Noncash Expense 3 month as first filed | Share-based Payment Arrangement, Noncash Expense 6 month | Share-based Payment Arrangement, Noncash Expense 6 month as first filed | Share-based Payment Arrangement, Noncash Expense 9 month | Share-based Payment Arrangement, Noncash Expense 9 month as first filed | Share-based Payment Arrangement, Noncash Expense 12 month | Share-based Payment Arrangement, Noncash Expense 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $7.09M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $16.36M 10-Q · filed 2026-08-06 | $22.57M derived: sum of 3 quarters · filed 2026-08-06 | $28.87M derived: sum of 4 quarters · filed 2026-08-06 | ||||
| 2026-03-31 | $9.27M 10-Q · filed 2026-05-07 | $15.48M derived: sum of 2 quarters · filed 2026-05-07 | $21.78M derived: sum of 3 quarters · filed 2026-05-07 | $28.16M derived: sum of 4 quarters · filed 2026-08-06 | ||||
| 2025-12-31 | $6.21M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $12.50M derived: sum of 2 quarters · filed 2026-02-26 | $18.88M derived: sum of 3 quarters · filed 2026-08-06 | $27.28M 10-K · filed 2026-02-26 | ||||
| 2025-09-30 | $6.30M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $12.68M derived: sum of 2 quarters · filed 2026-08-06 | $21.07M 10-Q · filed 2025-11-06 | $26.70M derived: sum of 4 quarters · filed 2026-08-06 | ||||
| 2025-06-30 | $6.38M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $14.78M 10-Q · filed 2026-08-06 | $20.41M derived: sum of 3 quarters · filed 2026-08-06 | $26.00M derived: sum of 4 quarters · filed 2026-08-06 | ||||
| 2025-03-31 | $8.39M 10-Q · filed 2026-05-07 | $14.03M derived: sum of 2 quarters · filed 2026-05-07 | $19.62M derived: sum of 3 quarters · filed 2026-05-07 | $25.40M derived: sum of 4 quarters · filed 2026-05-07 | ||||
| 2024-12-31 | $5.63M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $11.23M derived: sum of 2 quarters · filed 2026-02-26 | $17.01M derived: sum of 3 quarters · filed 2026-02-26 | $24.37M 10-K · filed 2026-02-26 | ||||
| 2024-09-30 | $5.60M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $11.38M derived: sum of 2 quarters · filed 2025-11-06 | $18.74M 10-Q · filed 2025-11-06 | $23.36M derived: sum of 4 quarters · filed 2026-02-26 | ||||
| 2024-06-30 | $5.78M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | $13.14M 10-Q · filed 2025-08-07 | $17.76M derived: sum of 3 quarters · filed 2026-02-26 | $22.41M derived: sum of 4 quarters · filed 2026-02-26 | ||||
| 2024-03-31 | $7.36M 10-Q · filed 2025-05-08 | $11.98M derived: sum of 2 quarters · filed 2026-02-26 | $16.63M derived: sum of 3 quarters · filed 2026-02-26 | $21.49M derived: sum of 4 quarters · filed 2026-02-26 | ||||
| 2023-12-31 | $4.62M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $9.27M derived: sum of 2 quarters · filed 2026-02-26 | $14.13M derived: sum of 3 quarters · filed 2026-02-26 | $20.24M 10-K · filed 2026-02-26 | ||||
| 2023-09-30 | $4.64M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | $9.51M derived: sum of 2 quarters · filed 2024-11-07 | $15.62M 10-Q · filed 2024-11-07 | $19.92M derived: sum of 4 quarters · filed 2025-03-03 | ||||
| 2023-06-30 | $4.87M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-09 | $10.98M 10-Q · filed 2024-08-09 | $15.28M derived: sum of 3 quarters · filed 2025-03-03 | $19.58M derived: sum of 4 quarters · filed 2025-03-03 | ||||
| 2023-03-31 | $6.11M 10-Q · filed 2024-05-10 | $10.41M derived: sum of 2 quarters · filed 2025-03-03 | $14.71M derived: sum of 3 quarters · filed 2025-03-03 | $18.95M derived: sum of 4 quarters · filed 2025-03-03 | ||||
| 2022-12-31 | $4.30M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-03 | $8.60M derived: sum of 2 quarters · filed 2025-03-03 | $12.84M derived: sum of 3 quarters · filed 2025-03-03 | $17.86M 10-K · filed 2025-03-03 | ||||
| 2022-09-30 | $4.30M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-08 | $8.53M derived: sum of 2 quarters · filed 2023-11-08 | $13.56M 10-Q · filed 2023-11-08 | $17.41M derived: sum of 4 quarters · filed 2024-02-29 | ||||
| 2022-06-30 | $4.24M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-09 | $9.26M 10-Q · filed 2023-08-09 | $13.11M derived: sum of 3 quarters · filed 2024-02-29 | $17.03M derived: sum of 4 quarters · filed 2024-02-29 | ||||
| 2022-03-31 | $5.02M 10-Q · filed 2023-05-09 | $8.87M derived: sum of 2 quarters · filed 2024-02-29 | $12.79M derived: sum of 3 quarters · filed 2024-02-29 | $18.88M derived: sum of 4 quarters · filed 2024-02-29 | ||||
| 2021-12-31 | $3.85M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-29 | $7.77M derived: sum of 2 quarters · filed 2024-02-29 | $13.85M derived: sum of 3 quarters · filed 2024-02-29 | $18.69M 10-K · filed 2024-02-29 | ||||
| 2021-09-30 | $3.92M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-08 | $10.00M derived: sum of 2 quarters · filed 2022-11-08 | $14.84M 10-Q · filed 2022-11-08 | $19.17M derived: sum of 4 quarters · filed 2023-03-01 | ||||
| 2021-06-30 | $6.08M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-09 | $10.92M 10-Q · filed 2022-08-09 | $15.25M derived: sum of 3 quarters · filed 2023-03-01 | $19.62M derived: sum of 4 quarters · filed 2023-03-01 | ||||
| 2021-03-31 | $4.83M 10-Q · filed 2022-05-10 | $9.17M derived: sum of 2 quarters · filed 2023-03-01 | $13.54M derived: sum of 3 quarters · filed 2023-03-01 | $20.05M derived: sum of 4 quarters · filed 2023-03-01 | ||||
| 2020-12-31 | $4.33M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-01 | $8.70M derived: sum of 2 quarters · filed 2023-03-01 | $15.22M derived: sum of 3 quarters · filed 2023-03-01 | $20.50M 10-K · filed 2023-03-01 | ||||
| 2020-09-30 | $4.37M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-09 | $10.88M derived: sum of 2 quarters · filed 2021-11-09 | $16.16M 10-Q · filed 2021-11-09 | $20.46M derived: sum of 4 quarters · filed 2022-03-11 | ||||
| 2020-06-30 | $6.51M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-09 | $11.79M 10-Q · filed 2021-08-09 | $16.09M derived: sum of 3 quarters · filed 2022-03-11 | $20.38M derived: sum of 4 quarters · filed 2022-03-11 | ||||
| 2020-03-31 | $5.28M 10-Q · filed 2021-05-07 | $9.58M derived: sum of 2 quarters · filed 2022-03-11 | $13.87M derived: sum of 3 quarters · filed 2022-03-11 | $17.90M derived: sum of 4 quarters · filed 2022-03-11 | ||||
| 2019-12-31 | $4.29M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-11 | $8.59M derived: sum of 2 quarters · filed 2022-03-11 | $12.62M derived: sum of 3 quarters · filed 2022-03-11 | $17.30M 10-K · filed 2022-03-11 | ||||
| 2019-09-30 | $4.29M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-06 | $8.33M derived: sum of 2 quarters · filed 2020-11-06 | $13.00M 10-Q · filed 2020-11-06 | $16.91M derived: sum of 4 quarters · filed 2021-03-15 | ||||
| 2019-06-30 | $4.03M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-07 | $8.71M 10-Q · filed 2020-08-07 | $12.62M derived: sum of 3 quarters · filed 2021-03-15 | $16.52M derived: sum of 4 quarters · filed 2021-03-15 | ||||
| 2019-03-31 | $4.67M 10-Q · filed 2020-05-11 | $8.58M derived: sum of 2 quarters · filed 2021-03-15 | $12.49M derived: sum of 3 quarters · filed 2021-03-15 | $16.69M derived: sum of 4 quarters · filed 2021-03-15 | ||||
| 2018-12-31 | $3.91M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-15 | $7.82M derived: sum of 2 quarters · filed 2021-03-15 | $12.01M derived: sum of 3 quarters · filed 2021-03-15 | $16.68M 10-K · filed 2021-03-15 | ||||
| 2018-09-30 | $3.91M derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-08 | $8.10M derived: sum of 2 quarters · filed 2019-11-08 | $12.77M 10-Q · filed 2019-11-08 | $16.95M derived: sum of 4 quarters · filed 2020-03-16 | ||||
| 2018-06-30 | $4.20M derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-09 | $8.86M 10-Q · filed 2019-08-09 | $13.04M derived: sum of 3 quarters · filed 2020-03-16 | $17.20M derived: sum of 4 quarters · filed 2020-03-16 | ||||
| 2018-03-31 | $4.67M 10-Q · filed 2019-05-10 | $8.85M derived: sum of 2 quarters · filed 2020-03-16 | $13.00M derived: sum of 3 quarters · filed 2020-03-16 | $17.30M derived: sum of 4 quarters · filed 2020-03-16 | ||||
| 2017-12-31 | $4.18M derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-16 | $8.34M derived: sum of 2 quarters · filed 2020-03-16 | $12.64M derived: sum of 3 quarters · filed 2020-03-16 | $17.09M 10-K · filed 2020-03-16 | ||||
| 2017-09-30 | $4.16M derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-09 | $8.45M derived: sum of 2 quarters · filed 2018-11-09 | $12.90M 10-Q · filed 2018-11-09 | $16.43M derived: sum of 4 quarters · filed 2019-03-15 | ||||
| 2017-06-30 | $4.30M derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-09 | $8.75M 10-Q · filed 2018-08-09 | $12.27M derived: sum of 3 quarters · filed 2019-03-15 | $15.82M derived: sum of 4 quarters · filed 2019-03-15 | ||||
| 2017-03-31 | $4.45M 10-Q · filed 2018-05-10 | $7.97M derived: sum of 2 quarters · filed 2019-03-15 | $11.53M derived: sum of 3 quarters · filed 2019-03-15 | $15.72M derived: sum of 4 quarters · filed 2019-03-15 | ||||
| 2016-12-31 | $3.52M derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-15 | $7.08M derived: sum of 2 quarters · filed 2019-03-15 | $11.27M derived: sum of 3 quarters · filed 2019-03-15 | $15.12M 10-K · filed 2019-03-15 | ||||
| 2016-09-30 | $3.56M derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-09 | $7.75M derived: sum of 2 quarters · filed 2017-11-09 | $11.60M 10-Q · filed 2017-11-09 | $10.48M 10-Q · filed 2016-11-09 | $15.73M derived: sum of 4 quarters · filed 2018-03-14 | |||
| 2016-06-30 | $4.20M derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-09 | $8.05M 10-Q · filed 2017-08-09 | $7.23M 10-Q · filed 2016-08-09 | $12.18M derived: sum of 3 quarters · filed 2018-03-14 | $15.11M derived: sum of 4 quarters · filed 2018-03-14 | |||
| 2016-03-31 | $3.85M 10-Q · filed 2017-05-10 | $3.40M 10-Q · filed 2016-05-10 | $7.98M derived: sum of 2 quarters · filed 2018-03-14 | $10.91M derived: sum of 3 quarters · filed 2018-03-14 | $14.44M derived: sum of 4 quarters · filed 2018-03-14 | |||
| 2015-12-31 | $4.13M derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-14 | $7.06M derived: sum of 2 quarters · filed 2018-03-14 | $10.59M derived: sum of 3 quarters · filed 2018-03-14 | $12.81M 10-K · filed 2018-03-14 | $11.68M 10-K · filed 2016-03-15 | |||
| 2015-09-30 | $2.93M derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-09 | $6.46M derived: sum of 2 quarters · filed 2016-11-09 | $8.69M 10-Q · filed 2016-11-09 | $12.02M derived: sum of 4 quarters · filed 2017-03-15 | ||||
| 2015-06-30 | $3.53M derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-09 | $5.76M 10-Q · filed 2016-08-09 | $9.09M derived: sum of 3 quarters · filed 2017-03-15 | $11.49M derived: sum of 4 quarters · filed 2017-03-15 | ||||
| 2015-03-31 | $2.22M 10-Q · filed 2016-05-10 | $5.55M derived: sum of 2 quarters · filed 2017-03-15 | $7.96M derived: sum of 3 quarters · filed 2017-03-15 | $10.12M derived: sum of 4 quarters · filed 2017-03-15 | ||||
| 2014-12-31 | $3.33M derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-15 | $5.73M derived: sum of 2 quarters · filed 2017-03-15 | $7.90M derived: sum of 3 quarters · filed 2017-03-15 | $9.28M 10-K · filed 2017-03-15 | $8.33M 10-K · filed 2015-03-26 | |||
| 2014-09-30 | $2.41M derived: 10-Q 9 month − 10-Q 6 month · filed 2015-11-13 | $4.57M derived: sum of 2 quarters · filed 2015-11-13 | $5.95M 10-Q · filed 2015-11-13 | $7.47M derived: sum of 4 quarters · filed 2016-03-15 | ||||
| 2014-06-30 | $2.17M derived: 10-Q 6 month − 10-Q 3 month · filed 2015-08-13 | $3.55M 10-Q · filed 2015-08-13 | $5.07M derived: sum of 3 quarters · filed 2016-03-15 | $7.29M derived: sum of 4 quarters · filed 2016-03-15 | ||||
| 2014-03-31 | $1.38M 10-Q · filed 2015-05-14 | $2.90M derived: sum of 2 quarters · filed 2016-03-15 | $5.12M derived: sum of 3 quarters · filed 2016-03-15 | |||||
| 2013-12-31 | $1.52M derived: 10-K 12 month − 10-Q 9 month · filed 2016-03-15 | $3.74M derived: sum of 2 quarters · filed 2016-03-15 | $6.09M 10-K · filed 2016-03-15 | |||||
| 2013-09-30 | $2.22M derived: 10-Q 9 month − 10-Q 6 month · filed 2014-11-13 | $4.57M 10-Q · filed 2014-11-13 | ||||||
| 2013-06-30 | $2.35M 10-Q · filed 2014-08-13 | |||||||
| 2012-12-31 | $6.67M 10-K · filed 2015-03-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Seaport Therapeutics, Inc. (SPTX) | United States | $1.131B | |
| Alto Neuroscience, Inc. (ANRO) | United States | $1.065B | -11.02 |
| MANNKIND CORP (MNKD) | United States | $1.058B | -30.41 |
| Latigo Biotherapeutics, Inc. (LTGO) | United States | $1.176B | |
| Jaguar Health, Inc. (JAGX) | United States | $1.184B | |
| Savara Inc (SVRA) | United States | $1.044B | -9.10 |
| MoonLake Immunotherapeutics (MLTX) | Switzerland | $1.031B | -5.43 |
| Pacira BioSciences, Inc. (PCRX) | United States | $1.020B | 69.03 |
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| LB PHARMACEUTICALS INC (LBRX) | United States | $1.220B | -10.87 |